What is the address of DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG?

The registered office of DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG is located at Engelstraat 97, 9040 Gent.

Is DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG still active?

Yes. According to the CBE (2 November 2026) DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG is active, legal situation “Normale toestand”, started on 17 September 2018.

Is DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG registered on Peppol?

Yes, DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG is registered on the Peppol network with ID 0208:0704663527.

What is the enterprise number of DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG?

The enterprise number of DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG is BE0704663527.

When was DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG founded?

DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG was founded on 17 September 2018.

Who are the directors of DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG?

According to the 2025 annual accounts, the directors of DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG are: Maarten De Wilde.

Is DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 September 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG make in 2025?

DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG posted a profit after taxes of € 311,301 in financial year 2025.

What is the revenue of DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG?

As a small company, DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 407,419.

DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG (Private Limited)

Dossier DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG, printed on 2 November 2026 from databakkes.be/en/0704663527/dr-maarten-de-wilde-internist-nefroloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG from Gent, company number BE0704663527, closed financial year 2025 with a result of € 311,301 after tax. For that financial year DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG recorded a gross margin of € 407,419 and equity of € 311,301. Compared with financial year 2024, the result moved from € 319,656 to € 311,301. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.

What it is worth Growing

€ 311,301

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 311,301

▼ 3% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 305,868

▲ € 293,303 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 311,301.

People and assets in 2025

Vehicles and equipment

€ 3,515

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 3,004

▲ 19% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 17,784

▼ 47% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 269,908 Gross margin 2022: € 269,908 First fiscal year in the series	€ 319,505 Gross margin 2023: € 319,505 ▲ 18% vs 2022 (€ 269,908) Favourable step	€ 417,478 Gross margin 2024: € 417,478 ▲ 31% vs 2023 (€ 319,505) Favourable step	€ 407,419 Gross margin 2025: € 407,419 ▼ 2% vs 2024 (€ 417,478) Unfavourable step	▼ 2%
Profit after taxes	€ 203,477 Profit after taxes 2022: € 203,477 First fiscal year in the series	€ 242,652 Profit after taxes 2023: € 242,652 ▲ 19% vs 2022 (€ 203,477) Favourable step	€ 319,656 Profit after taxes 2024: € 319,656 ▲ 32% vs 2023 (€ 242,652) Favourable step	€ 311,301 Profit after taxes 2025: € 311,301 ▼ 3% vs 2024 (€ 319,656) Unfavourable step	▼ 3%
Equity	€ 208,824 Equity 2022: € 208,824 First fiscal year in the series	€ 249,998 Equity 2023: € 249,998 ▲ 20% vs 2022 (€ 208,824) Favourable step	€ 0 Equity 2024: € 0 ▼ 100% vs 2023 (€ 249,998) Unfavourable step	€ 311,301 Equity 2025: € 311,301 Unchanged (€ 0) Favourable step
Total debts	€ 24,044 Total debts 2022: € 24,044 First fiscal year in the series	€ 29,579 Total debts 2023: € 29,579 ▲ 23% vs 2022 (€ 24,044) Unfavourable step	€ 236,017 Total debts 2024: € 236,017 ▲ € 206,438 vs 2023 (€ 29,579) Unfavourable step	€ 20,788 Total debts 2025: € 20,788 ▼ 91% vs 2024 (€ 236,017) Favourable step	▼ 91%
Cash	€ 210,290 Cash 2022: € 210,290 First fiscal year in the series	€ 4,138 Cash 2023: € 4,138 ▼ 98% vs 2022 (€ 210,290) Unfavourable step	€ 12,566 Cash 2024: € 12,566 ▲ 204% vs 2023 (€ 4,138) Favourable step	€ 305,868 Cash 2025: € 305,868 ▲ € 293,303 vs 2024 (€ 12,566) Favourable step	▲ € 293,303
Retained profit	€ 208,824 Retained profit 2022: € 208,824 First fiscal year in the series	€ 249,998 Retained profit 2023: € 249,998 ▲ 20% vs 2022 (€ 208,824) Favourable step	€ 0 Retained profit 2024: € 0 ▼ 100% vs 2023 (€ 249,998) Unfavourable step	€ 311,301 Retained profit 2025: € 311,301 Unchanged (€ 0) Favourable step
Dividend	€ 52,000 Dividend 2022: € 52,000 First fiscal year in the series	€ 201,477 Dividend 2023: € 201,477 ▲ 287% vs 2022 (€ 52,000) Unchanged	€ 569,654 Dividend 2024: € 569,654 ▲ 183% vs 2023 (€ 201,477) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 569,654) Unchanged	▼ 100%
Balance sheet total	€ 232,868 Balance sheet total 2022: € 232,868 First fiscal year in the series	€ 279,577 Balance sheet total 2023: € 279,577 ▲ 20% vs 2022 (€ 232,868) Unchanged	€ 236,017 Balance sheet total 2024: € 236,017 ▼ 16% vs 2023 (€ 279,577) Unchanged	€ 332,089 Balance sheet total 2025: € 332,089 ▲ 41% vs 2024 (€ 236,017) Unchanged	▲ 41%

Key figures of DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG?

What happened at DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 28, 2026 New annual accounts for financial year 2025: profit of € 311,301 (▼ 3% vs 2024). Source: NBB ↗
Sep 17, 2018 New establishment in Mouscron. KBO
Sep 17, 2018 Start of the company according to the CBE. KBO

In short

From € 203,477 profit in 2022 to € 311,301 profit in 2025.

Paid € 336,844 in corporate taxes since 2022.

Best year ever: 2024, with € 319,656 profit.

Paid out € 823,131 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Maarten De Wilde

DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG

Behind DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG is Maarten De Wilde.

Directors

According to the 2025 annual accounts

Maarten De Wilde

bestuurder

Establishments

Establishment units

Physical locations of this company

Registered office

Engelstraat 97

9040 Gent

2.280.205.823

Fecamplaan 49

7700 Mouscron

Active since 17 September 2018

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0704.663.527
VAT number: BE 0704.663.527
Registered office: Engelstraat 97, 9040 Gent
Names & denominations: DR. MAARTEN DE WILDE, INTERNIST-NEFROLOOG
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 17 September 2018
Peppol: Active · Active since 5 Jan 2026

View on CBE Public ↗ Annual accounts (NBB) ↗